article thumbnail

Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval

MedCity News

The post Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval appeared first on MedCity News. Approval of Syndax’s Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin.

article thumbnail

Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M

MedCity News

Acadia Pharmaceuticals did not disclose the buyer of the priority review voucher. The biotech received the voucher last year alongside the regulatory decision that made its drug Daybue the first FDA-approved treatment for the rare disease Rett syndrome.

FDA 298
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender

MedCity News

Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics.

article thumbnail

Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

MedCity News

Neurotech Pharmaceuticals surgically implanted cell and gene therapy, Encelto, is now FDA approved to treat macular telangectasia type 2 (MacTel). Its the first therapy for this rare retinal degeneration disorder. The post Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder appeared first on MedCity News.

FDA 298
article thumbnail

Vertex Pharma’s Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds

MedCity News

Vertex Pharmaceuticals Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The twice-daily pill is the first in a new class of medicines that block a key pathway in the peripheral nervous system.

FDA 276
article thumbnail

The Financial Potential of Convertible Notes in the Pharmaceutical Sector

MedCity News

The post The Financial Potential of Convertible Notes in the Pharmaceutical Sector appeared first on MedCity News. These notes serve not only as a means to raise capital but also as a bridge to future financing rounds or significant liquidity events.

article thumbnail

It's a monster MASH for Madrigal as Rezdiffra has caught on in a flash

Fierce Pharma

Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potentia | Forget about the “bumpiness” analysts expected from Madrigal Pharmaceuticals’ launch of potential blockbuster Rezdiffra.

Sales 252